Needham raised the firm’s price target on Arcellx (ACLX) to $96 from $81 and keeps a Buy rating on the shares. The firm updated its multiple myeloma market model to reflect updated pricing assumptions for anito-cel based on current pricing for competitor commercial CAR-Ts Carvykti and Abecma. It now estimates $10B in combined global sales for anito-cel in multiple myeloma by 2037.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter